1. Main associations between PLAUR (urokinase plasminogen activator receptor) single nucleotide polymorphisms (SNPs) and markers of airway remodelling, and immunohistochemical analyses PMID: 26869673
2. Our study implies that both soluble UPAR and advanced echocardiography are useful diagnostic tools for identifying patients with diabetes at risk of future clinical heart disease PMID: 26951602
3. Soluble urokinase plasminogen activation receptor (suPAR) is an emerging new biomarker for prognosticating cardiovascular disease PMID: 27052059
4. we review the human and mouse Ly6/uPAR family gene and protein structure and genomic organization, expression, functions, and evolution, and introduce new names for novel family members PMID: 27098205
5. The effect of LIF and uPAR on trophoblast migration and invasion was mediated by PI3K/AKT signaling pathway. PMID: 27133045
6. suPAR levels were significantly higher Behcet's disease patients. PMID: 27171829
7. This is the first report that PGE2 -induced uPAR expression, which stimulates invasiveness of human gastric cancer AGS cells, is mediated by the EP2 receptor-dependent Src/EGFR/JNK1/2, Erk1/2/AP-1, and Src/EGFR/JNK1/2, Erk1/2/NF-kappaB cascades. PMID: 27377703
8. Results provide evidence that uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R. PMID: 27502396
9. Levels of circulating cleaved soluble forms plasminogen activator urokinase receptor (DIIDIII-suPAR) in acute myeloid leukemia (AML) patients are higher as compared to controls and significantly decrease after the conditioning. PMID: 27517491
10. Sera and tissues from malignant mesothelioma (MM) patients showed significantly high plasminogen activator urokinase receptor (uPAR) levels, suggesting the pathogenic role of uPAR in the tumor biology of MM. PMID: 27602956
11. This study provides novel data that elevated airway and blood uPAR is a feature of asthma and that blood uPAR is particularly related to severe, nonatopic asthma. PMID: 27624865
12. PLAUR to be essential for activation of Checkpoint kinase 1 (CHK1); maintenance of cell cycle arrest after DNA damage in a TP53-dependent manner; expression, nuclear import and recruitment to DNA-damage foci of RAD51 recombinase, the principal protein involved in the homologous recombination repair pathway. PMID: 27685627
13. Serum soluble urokinase-type plasminogen activator receptor as a serum marker of inflammatory response that leads to tissue damage and surgical complication PMID: 27759946
14. uPAR and mTORC2 are components of a single cell-signaling pathway. PMID: 27777073
15. Plasma plasminogen activator urokinase receptor (P-suPAR) concentrations are elevated in acute alcohol pancreatitis (AAP) and correlate with the severity of the disease, suggesting P-suPAR may serve as a prognostic marker for AAP severity on admission. PMID: 27841794
16. Results suggest that soluble urokinase-type plasminogen activator receptor levels are positively correlated with severity of acute pancreatitis. PMID: 27914940
17. Studies indicate the feasibility of combining two U-PA receptor (uPAR)-targeted probes in a preclinical head and neck cancer model. PMID: 28039488
18. Binding of uPAR to VN triggers integrin-mediated signals, which result in ERK1-2 and RAC activation, accumulation of ROS, and senescence. PMID: 28086938
19. Elevated baseline soluble urokinase receptor concentrations independently associate with new-onset microalbuminuria in subjects at increased risk of developing type 2 diabetes. PMID: 28091558
20. We report on the impact of bispecific targeting on the toxicity risks associated with targeting of EGFR and uPAR . Our results show that eBAT is safe and potentially effective at biologically active doses despite EGFR targeting, supporting further translation for patients with sarcomas and other EGFR-expressing malignancies. PMID: 28193671
21. Improved positron emission tomography imaging of glioblastoma cancer using novel (68)Ga-labeled peptides targeting the urokinase-type plasminogen activator receptor (uPAR). PMID: 28316028
22. Patients with cancer were significantly older and had a higher burden of comorbidities and previous cancer diagnoses compared to patients who were not diagnosed with cancer. Previous cancer, C-reactive protein (CRP) and suPAR were significantly associated with newly diagnosed cancer during follow-up in multiple logistic regression analyses adjusted for age, sex and CRP PMID: 28393357
23. Increased uPAR expression was detected in the derma of psoriatic lesions and in the stroma surrounding tumor cells in basal cell carcinomas. PMID: 28429105
24. To develop enzyme-resistant analogues, we applied here the Retro-Inverso (RI) approach, whereby the topology of the side chains is maintained by inverting the sequence of the peptide and the chirality of all residues. Molecular dynamics suggests that peptide RI-3 adopts the turn structure typical of uPAR-FPR1 antagonists PMID: 28465589
25. suPAR levels are significantly elevated in hemodialysis patients with ESRD and remain associated with adverse outcomes. PMID: 28495863
26. High Upar expression is associated with breast cancer. PMID: 28498427
27. These findings may show that presenting a high level of suPAR in migraine patients with attack and aura results to predisposition to occurring on the symptoms and that high levels of suPAR, procalcitonin and fibrinogen in patients with migraine result in neurogenic inflammation during migraine headaches. PMID: 28553881
28. Plasma levels of intact and cleaved urokinase plasminogen activator receptor do not hold important predictive or prognostic information in men with clinically localised prostate cancer. PMID: 28607123
29. IFN-gamma, CXCL16 and uPAR are promising as effective biomarkers of disease activity, renal damage, and the activity of pathological lesions in systemic lupus erythematosus. PMID: 28628472
30. The synergy of circulating factor suPAR and APOL1 G1 or G2 on alphavbeta3 integrin activation is a mechanism for CKD. PMID: 28650456
31. Circulating soluble uPAR levels are higher in patients with peripheral arterial disease, particularly in those with extensive atherosclerosis and are predictive of long term cardiovascular and PAD-related outcomes. PMID: 28728756
32. suPAR may be a good novel biomarker for systemic subclinical inflammation and immune activation linked to adolescent obesity. PMID: 28749394
33. uPAR and TF could potentially be attractive targets for molecular imaging and therapy in oral squamous cell carcinoma due to high positive expression rates and tumor-specific expression patterns. High uPAR expression was significantly associated with a reduced survival. PMID: 28841839
34. the present study demonstrated that EGF induced aggressiveness of gastric cancer cells by activating epithelial to mesenchymal transition, which involved the activation of the ERK1/2 pathway and, subsequently, uPAR expression PMID: 28849196
35. The results establish GDE3 as a negative regulator of the uPAR signaling network and, furthermore, highlight GPI-anchor hydrolysis as a cell-intrinsic mechanism to alter cell behavior. PMID: 28849762
36. Patients with high suPAR levels were more likely to have progression of their kidney disease. PMID: 28873129
37. Data confirmed PLAUR and CDH11, both targets of miR-335, to be overexpressed in gastric cancer tissues. PMID: 29075357
38. This study shows that the D2A sequence of the UPAR induces cell growth through alphaVbeta3 integrin and EGFR. PMID: 29184982
39. suPAR is associated with the Coronary Artery Calcification score and is a risk factor for new-onset CVD in patients undergoing hemodialysis. PMID: 29734173
40. Serum and urine concentration of suPAR did not different between different clinical patterns of nephrotic syndrome in children, regardless the immunosuppressive treatment used. PMID: 29775445
41. In acutely admitted patients with COPD, elevated PLAUR levels were associated with increased risk of mortality. PMID: 29783959
42. High expression of U-PAR is associated with breast cancer. PMID: 29893327
43. results demonstrated that PLAUR induces geftinib-resistance through EGFR/p-AKT/survivin signaling pathway in gefitinib-resistant human lung adenocarcinoma cells. PLAUR could be a novel therapeutic target for gefitinib-resistant NSCLC patients. PMID: 29961070

HGNC: 9053

OMIM: 173391

KEGG: hsa:5329

STRING: 9606.ENSP00000339328

UniGene: Hs.466871